We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

This study is currently recruiting participants.
Verified June 2017 by Prof. W. Janni, University of Ulm
Sponsor:
ClinicalTrials.gov Identifier:
NCT02035813
First Posted: January 14, 2014
Last Update Posted: June 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Prof. W. Janni, University of Ulm
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)